卡瑞利珠单抗免疫治疗对晚期食管癌患者的临床疗效与安全性分析

Clinical Effect and Safety Analysis of Karelizumab Immunotherapy for Patients with Advanced Esophageal Cancer

目的分析与研究卡瑞利珠单抗免疫治疗对晚期食管癌患者的临床疗效与安全性。方法研究对象为我院收治的80例食管癌患者,纳入期限为2020年10月-2021年10月,随机分组,两组均为40例。对照组接受白蛋白紫杉醇、顺铂治疗,观察组在此基础上联合卡瑞利珠单抗免疫治疗。统计两组临床疗效、治疗前后肿瘤标志物水平、免疫功能相关指标、血清外周血程序性死亡受体1(PD-1)、程序性死亡受体配体1(PD-L1)水平及不良反应发生情况。结果观察组疾病控制率显著高于对照组(P<0.05)。治疗后,观察组肿瘤标志物水平均显著低于对照组(P<0.05)。治疗后,观察组CD3+、CD4+、CD3+/CD4+水平均显著高于对照组(P<0.05)。治疗后,观察组PD-1、PD-L1水平显著低于对照组(P<0.05)。两组不良反应发生率无明显差异(P>0.05)。结论对晚期食管癌患者采用卡瑞利珠单抗免疫治疗,效果确切,有助于改善患者免疫功能,降低肿瘤标志物水平,调节血清PD-1、PD-L1表达,且安全性良好,值得推广应用。

Objective To analyze and study clinical effect and safety of karelizumab immunotherapy for patients with advanced esophageal cancer.Methods The paper chose 80 esophageal cancer patients admitted to our hospital from October 2020 to October 2021 as study objects,and divided them into two groups randomly,with 40 cases in each groups.Control group was treated with albumin paclitaxel and cisplatin,while observation group with immunotherapy combined with karelizumab on the basis.Clinical effect,tumor marker levels before and after treatment,immune function related indicators,serum levels of programmed death receptor 1(PD-1)and programmed death receptor ligand 1(PD-L1)in both groups,incidence of adverse reactions were calculated.Results Disease control rate in observation group was significantly higher than control group(P<0.05).After treatment,average level of tumor marker water in observation group was significantly lower than control group(P<0.05).After treatment,levels of CD3+,CD4+and CD3+/CD4+in observation group were significantly higher than control group(P<0.05).After treatment,levels of PD-1 and PD-L1 in observation group were significantly lower than control group(P<0.05).There was no significant difference in incidence of adverse reactions between two groups(P>0.05).Conclusion Karelizumab immunotherapy can achieve definite effect for advanced esophageal cancer patients,can improve immune function,reduce tumor marker levels,regulate serum PD-1 and PD-L1 expression of patients,with good safety,which is worthy of promotion and application.